Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Acetylcholine receptor antagonists are drugs that block acetylcholine from binding to its receptors, inhibiting parasympathetic nerve signals and affecting functions like muscle contraction, gland secretion, and neurotransmission. Advancements in drug development, like new formulations and targeted therapies enhance efficacy and safety, and greater investment in pharmaceuticals and treatment accessibility boosts the market growth of acetylcholine receptor antagonists.

/EIN News/ -- New York, USA, March 06, 2025 (GLOBE NEWSWIRE) -- Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Acetylcholine receptor antagonists are drugs that block acetylcholine from binding to its receptors, inhibiting parasympathetic nerve signals and affecting functions like muscle contraction, gland secretion, and neurotransmission. Advancements in drug development, like new formulations and targeted therapies enhance efficacy and safety, and greater investment in pharmaceuticals and treatment accessibility boosts the market growth of acetylcholine receptor antagonists. 

DelveInsight’s 'Acetylcholine Receptor Antagonists Pipeline Insight 2025' report provides comprehensive global coverage of pipeline acetylcholine receptor antagonists in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the acetylcholine receptor antagonists pipeline domain.

Key Takeaways from the Acetylcholine Receptor Antagonists Pipeline Report

• DelveInsight’s acetylcholine receptor antagonists pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline acetylcholine receptor antagonists. 
• Key acetylcholine receptor antagonists companies such as Axsome Therapeutics, Bristol Myers Squibb, Bionomics, Apnimed,  Seefunge Pharmaceutical Technology, Vyluma, Santen Pharmaceutical, CSPC Ouyi Pharmaceutical Co., Ltd., Suven Life Sciences Limited, Nobelpharma, Cloudbreak Therapeutics, Neurocrine Biosciences, and others are evaluating new acetylcholine receptor antagonist drugs to improve the treatment landscape.
• Promising pipeline acetylcholine receptor antagonists such as AXS-05, COBENFY, BNC210, AD-109, OS-001, NVK-002, STN-10127, Pilocarpine HCl Ophthalmic Solution, SUVN-911,  NPC-22, CBT-009, NBI-1076986, and others are under different phases of acetylcholine receptor antagonists clinical trials.
• In January 2025, Zai Lab Limited announced that China’s National Medical Products Administration (NMPA) had accepted the New Drug Application (NDA) for KarXT to treat schizophrenia in adults. The NDA submission is supported by the results from a Phase 1 China Pharmacokinetics (PK) study, the Phase III China study (ZL-2701-001), and data from the global EMERGENT clinical programs.
• In October 2024, Zai Lab Limited announced positive topline results from the company’s Phase III multi-center trial evaluating the safety and efficacy of KarXT (xanomeline and trospium chloride) in China. Consistent with previous global studies, the registrational bridging trial met its primary endpoint, with KarXT demonstrating a statistically significant 9.2-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo at Week 5 (-16.9 KarXT vs. -7.7 placebo, p=0.0014).
• In August 2024, In a recent study, the investigational drug PIPE-307 effectively induced OPC differentiation and remyelination in MS donor human brain tissue and an animal model and restored lost function in an MS mouse model. The investigational drug, called PIPE-307, is a novel, oral, CNS-penetrating small molecule targeting the M1 muscarinic acetylcholine receptor (M1R).
• In May 2024, Neurocrine Biosciences, Inc. announced the initiation of its Phase I first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1076986 in healthy adult participants. NBI-1076986 is an investigational, oral, M4 subtype-selective muscarinic acetylcholine receptor antagonist for the potential treatment of movement disorders that was discovered and developed by Neurocrine Biosciences.

Request a sample and discover the recent advances in acetylcholine receptor antagonist drugs @ Acetylcholine Receptor Antagonists Pipeline Report

The acetylcholine receptor antagonists pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage acetylcholine receptor antagonist drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the acetylcholine receptor antagonists clinical trial landscape. 

Acetylcholine Receptor Antagonists Overview

Acetylcholine receptor (AChR) antagonists are compounds that inhibit the action of acetylcholine (ACh) at its receptors, leading to a reduction in cholinergic signaling. These antagonists can be classified based on their target receptors into muscarinic and nicotinic antagonists. Muscarinic antagonists, such as atropine and scopolamine, block the muscarinic ACh receptors (mAChRs) found in the central and peripheral nervous system, leading to effects like pupil dilation, decreased glandular secretion, and reduced smooth muscle contraction. They are used in various medical conditions, including bradycardia, motion sickness, and overactive bladder. 

Nicotinic antagonists, such as tubocurarine and hexamethonium, block nicotinic ACh receptors (nAChRs) at neuromuscular junctions or autonomic ganglia, resulting in muscle relaxation or autonomic blockade, respectively. These drugs are commonly used as muscle relaxants during anesthesia or to manage hypertension.

AChR antagonists have significant clinical relevance but also come with potential side effects due to their widespread effects on the autonomic and somatic nervous systems. Muscarinic antagonists can cause dry mouth, blurred vision, constipation, and cognitive impairment, especially in elderly patients. Nicotinic antagonists, particularly those affecting the neuromuscular junction, can lead to paralysis and respiratory depression if administered in excessive doses. 

Despite these risks, they remain critical in medical practice, from treating respiratory conditions like COPD (with ipratropium) to managing anesthesia-induced paralysis in surgery. Research into selective AChR antagonists is ongoing, with efforts to develop more targeted therapies that minimize systemic side effects while effectively modulating cholinergic signaling.

Find out more about acetylcholine receptor antagonist drugs @ Acetylcholine Receptor Antagonists Analysis

A snapshot of the Pipeline Acetylcholine Receptor Antagonist Drugs mentioned in the report:

Drugs	Company	Phase	Indication	RoA
AXS-05	Axsome Therapeutics	III	Agitation, Alzheimer Disease	Oral
COBENFY	Bristol Myers Squibb	III	Psychotic disorders	Oral
BNC210	Bionomics	III	Anxiety disorders	Oral
AD-109	Apnimed	III	Obstructive Sleep Apnea	Oral
CBT-009	Cloudbreak Therapeutics	Phase I/II	Progressive Myopia	Eyedrop aqueous solution

Learn more about the emerging acetylcholine receptor antagonists @ Acetylcholine Receptor Antagonists Clinical Trials

Acetylcholine Receptor Antagonists Therapeutics Assessment

The acetylcholine receptor antagonists pipeline report proffers an integral view of the emerging acetylcholine receptor antagonists segmented by stage, product type, molecule type, and route of administration.

Scope of the Acetylcholine Receptor Antagonists Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
• Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy
• Key Acetylcholine Receptor Antagonists Companies: Axsome Therapeutics, Bristol Myers Squibb, Bionomics, Apnimed,  Seefunge Pharmaceutical Technology, Vyluma, Santen Pharmaceutical, CSPC Ouyi Pharmaceutical Co., Ltd., Suven Life Sciences Limited, Nobelpharma, Cloudbreak Therapeutics, Neurocrine Biosciences and others.
• Key Acetylcholine Receptor Antagonists Pipeline Therapies: AXS-05, COBENFY, BNC210, AD-109, OS-001, NVK-002, STN-10127, Pilocarpine HCl Ophthalmic Solution, SUVN-911,  NPC-22, CBT-009, NBI-1076986 and others.

Dive deep into rich insights for new acetylcholine receptor antagonists, visit @ Acetylcholine Receptor Antagonists Drugs

Table of Contents

1.	Acetylcholine Receptor Antagonists Pipeline Report Introduction
2.	Acetylcholine Receptor Antagonists Pipeline Report Executive Summary
3.	Acetylcholine Receptor Antagonists Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Acetylcholine Receptor Antagonists Clinical Trial Therapeutics
6.	Acetylcholine Receptor Antagonists Pipeline: Late-Stage Products (Pre-registration)
7.	Acetylcholine Receptor Antagonists Pipeline: Late-Stage Products (Phase III)
8.	Acetylcholine Receptor Antagonists Pipeline: Mid-Stage Products (Phase II)
9.	Acetylcholine Receptor Antagonists Pipeline: Early-Stage Products (Phase I)
10.	Acetylcholine Receptor Antagonists Pipeline Therapeutics Assessment
11.	Inactive Products in the Acetylcholine Receptor Antagonists Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Acetylcholine Receptor Antagonists Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the acetylcholine receptor antagonists pipeline therapeutics, reach out @ Acetylcholine Receptor Antagonists Therapeutics

Related Reports

Muscarinic Acetylcholine Receptor (mAChR) Antagonist Pipeline

Muscarinic Acetylcholine Receptor (mAChR) Antagonist Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key mAChR antagonist companies, including Bristol Myers Squibb, Neurocrine Biosciences, Novartis, among others.

Muscarinic Acetylcholine Receptor M1 Antagonist Pipeline

Muscarinic Acetylcholine Receptor M1 Antagonist Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key mAChR M1 antagonist companies, including Onix Pharmaceuticals, Bristol-Myers Squibb, WinSanTor, Apnimed, among others.

Muscarinic Acetylcholine Receptor M2 Antagonist Pipeline

Muscarinic Acetylcholine Receptor M2 Antagonist Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key mAChR M2 antagonist companies, including Boehringer Ingelheim Pharma KG, Karuna Therapeutics, Bristol-Myers Squibb, Tocris Bioscience, among others.

Muscarinic Acetylcholine Receptor M3 Antagonist Pipeline

Muscarinic Acetylcholine Receptor M3 Antagonist Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key mAChR M3 antagonist companies, including Astellas Pharma, Novartis, Teva Pharmaceutical Industries, among others.

DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.

Other Business Consulting Services

Healthcare Conference Coverage

Pipeline Assessment

Healthcare Licensing Services

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Contact Us
                    
                    Shruti Thakur 
                    
                    info@delveinsight.com 
                    
                    +14699457679
                    
                    www.delveinsight.com